AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03814421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent (40mg as a bolus injection daily for 72hours)
Description: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
Study NCT00228215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS Intervention
Description: A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
Study NCT02710162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro Mouth Pressure Meter
Description: The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
Study NCT02710162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa Oral Performance Instrument
Description: The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
Study NCT02710162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Myography
Description: The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
Study NCT02710162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
Study NCT02710162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic Swallowing Study
Description: Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
Study NCT02710162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing
Description: Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
Study NCT02710162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing Related Quality of Life Questionnaire
Description: Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
Study NCT02710162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Oral Intake Scale
Description: The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
Study NCT02710162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
Description: The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
Study NCT02710162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eating Assessment Tool-10
Description: The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
Study NCT02710162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communicative Effectiveness Survey
Description: The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
Study NCT02710162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Center for Neurologic Studies Bulbar Function Scale
Description: The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
Study NCT04711681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Behavior Supports in Middle Schools
Description: 2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)
Study NCT04711681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Behavior Supports in Middle Schools
Description: 1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
Study NCT02954315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Study NCT03356704 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Observational study
Study NCT00372918 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transnasal Esophagoscopy
Description: fiberoptic exam of esophagus thru nares
Study NCT00912561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intense aerobic exercise
Description: 3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
Study NCT01655160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention group
Description: The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
Study NCT03785028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: working memory and attention
Description: working memory and attention tasks
Study NCT02341469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated ediagnostic approach (IeDA)
Description: IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~* REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~* The training of nurses on IMCI and REC.~* A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~* A supervision system conducted implemented by district managers to provide support and guidance to health centres.~* A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres.
Study NCT00793273 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
Study NCT03271983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole gel 1
Description: RLD gel
Study NCT03271983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole gel 2
Description: generic gel
Study NCT03271983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole cream
Description: generic cream
Study NCT04678076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen Lysine
Description: A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
Study NCT04678076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen Oral Product
Description: A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
Study NCT01781273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
Study NCT01781273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: 100 mL cranberry juice is provided in a 250 ml container.
Study NCT01781273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry juice
Description: 100 mL cranberry juice is provided in a 250 ml container.
Study NCT01246908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered twice per day for six weeks.
Study NCT01246908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX157 (TriRima)
Description: One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
Study NCT03740984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.
Description: During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
Study NCT03740984 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.
Description: During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
Study NCT01319331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha 1-Antitrypsin (AAT, Aralast NP)
Description: Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
Study NCT00606047 — intervention group
Intervention type: RADIATION
Intervention: Magnetic resonance imaging (MRI)
Description: Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
Study NCT01565304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER Through Choices
Description: 10-session group-based sexual education curriculum
Study NCT03844295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Inspire® Upper Airway Stimulation System
Description: At first, INSPIRE® device will be active a month
Study NCT03844295 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated Inspire® Upper Airway Stimulation System
Description: After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month.
Study NCT01602133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral venous puncture
Description: Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
Study NCT00593242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of autologous cord blood
Description: infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
Study NCT00593242 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurodevelopmental outcomes
Description: historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
Study NCT02353143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1112
Description: Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).
Study NCT00898547 — intervention group
Intervention type: OTHER
Intervention: immunoenzyme technique
Study NCT00898547 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT02954380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zio
Description: long term continuous monitoring
Study NCT03789019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Study NCT04136444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study NCT03743961 — intervention group
Intervention type: OTHER
Intervention: geriatric intervention
Description: Geriatric intervention
Study NCT00817128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEPT
Description: Pain Exposure Physical Therapy
Study NCT00817128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBO standard
Description: Standard therapy as defined in CBO guideline 2006
Study NCT02132442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol, placebo
Description: Ergocalciferol 50000 IU capsules Microcrystalline cellulose
Study NCT02132442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergocalciferol, placebo
Description: Ergocalciferol 50000 IU capsules Microcrystalline cellulose
Study NCT01940978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate ER
Description: Watson generic, starting dose 18mg QD
Study NCT01940978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate ER
Description: Watson generic, starting dose 18mg QD
Study NCT01940978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: cyproheptadine hydrochloride
Study NCT01711385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Description: Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
Study NCT03290482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Barium Esophagram
Description: Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
Study NCT03290482 — intervention group
Intervention type: DEVICE
Intervention: EsophaCap
Description: Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
Study NCT03290482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physical Examination and Questionnaires
Description: Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
Study NCT04918056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hematological Analysis and Genetical Analysis
Description: Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).~Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay.
Study NCT02946931 — intervention group
Intervention type: DRUG
Intervention: Prizbind®
Description: Prizbind®
Study NCT02769897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
Study NCT01845987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
Study NCT01044667 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GI and Quality of Life Assessment
Study NCT01845987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959
Description: CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
Study NCT02108262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
Study NCT02987855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Closed syringe harvesting subdermal fat
Study NCT02987855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADcSVF isolation
Description: Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
Study NCT02987855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline IV
Description: Normal Saline IV containing autologous AD-cSVF
Study NCT02681263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
Study NCT02403791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear Ultrasonic Sounder
Description: Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
Study NCT02403791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside X-ray Machine
Description: Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
Study NCT04040426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human split thickness skin allograft
Description: Application of a fenestrated human skin graft
Study NCT04040426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing
Study NCT04040426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Outer Dressing Applicaiton
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing
Study NCT04040426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot